GLP-1 and Your Heart: The Trial Data Explained — A Complete Patient Guide

Table of Contents

1. The Question That Started It All
2. What Are Cardiovascular Outcome Trials?
3. The LEADER Trial: Liraglutide
4. SUSTAIN 6: Injectable Semaglutide
5. The SELECT Trial: The Game Changer
6. The SOUL Trial: Oral Semaglutide
7. The Meta-Analysis: 71,000 Patients, One Consistent Answer
8. Mechanism 1: Blood Pressure Reduction
9. Mechanism 2: Endothelial Function and Nitric Oxide
10. Mechanism 3: Anti-Inflammatory Effects
11. Mechanism 4: Cholesterol and Triglyceride Improvement
12. Mechanism 5: Plaque Stabilization
13. Mechanism 6: Direct Effects on Immune Cells
14. Heart Failure: STEP-HFpEF and SUMMIT
15. What This Means for You

The Question That Started It All

Most people who take a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound think of it as a weight loss drug. Or a diabetes drug. And it is both of those things. But the cardiovascular data behind these medications is not just good. It is some of the strongest evidence in modern medicine. And most people taking these medications right now have no idea it exists. For years, the big question was simple: do GLP-1 medications actually prevent heart attacks and strokes, or do they just improve numbers on a lab report? Better cholesterol, lower blood sugar, less weight. Those are nice. But do they translate into fewer people dying? To answer that, researchers ran some of the largest and most rigorous clinical trials ever conducted. Tens of thousands of patients. Years of follow-up. Real outcomes. Not just cholesterol numbers, but actual heart attacks, actual strokes, and actual deaths. The answer was definitive. And it changed the way these medications are used. This guide walks through every landmark trial, explains the six mechanisms behind the heart protection, covers the emerging heart failure data, and explains why GLP-1 medications are now considered cardiovascular medicine, not just metabolic drugs.

What Are Cardiovascular Outcome Trials?

Before diving into the data, it is important to understand what a cardiovascular outcome trial (CVOT) is and why it matters. A CVOT is a large, randomized, placebo-controlled trial designed to answer one question: does this medication reduce the risk of heart attacks, strokes, and cardiovascular death? These trials enroll thousands of patients at high cardiovascular risk, follow them for years, and count actual events. Not lab values. Events. The primary endpoint in most CVOTs is called MACE, which stands for major adverse cardiovascular events. It is a composite of three outcomes: death from cardiovascular causes, nonfatal heart attack, and nonfatal stroke. If a medication reduces MACE, it means fewer people are having heart attacks, strokes, and cardiovascular deaths. These trials are the gold standard. They are the reason the FDA approves cardiovascular indications for these medications. And the GLP-1 data from these trials is remarkably consistent.

The LEADER Trial: Liraglutide

The LEADER trial was the first to prove cardiovascular superiority for a GLP-1 medication. It enrolled over 9,300 patients with type 2 diabetes and high cardiovascular risk and randomized them to liraglutide (Victoza) or placebo. After nearly four years of follow-up, liraglutide reduced the composite of cardiovascular death, heart attack, and stroke by 13 percent (hazard ratio 0.87). But here is what really turned heads: all-cause mortality, death from any cause, dropped by 15 percent (hazard ratio 0.85). That is not just preventing events. That is keeping people alive longer. The mortality reduction was driven primarily by a 22 percent reduction in cardiovascular death (hazard ratio 0.78). LEADER was the trial that established GLP-1 medications as cardiovascular drugs, not just glucose-lowering drugs.

SUSTAIN 6: Injectable Semaglutide

SUSTAIN 6 tested injectable semaglutide in about 3,300 patients with type 2 diabetes and established cardiovascular or kidney disease. The result was a striking 26 percent reduction in major adverse cardiovascular events (hazard ratio 0.74). The benefit was driven largely by a 39 percent reduction in nonfatal stroke (hazard ratio 0.61). This was the trial that put semaglutide on the cardiovascular map. A 26 percent reduction in MACE is a large effect size for a cardiovascular trial. For context, many widely used heart medications produce reductions in the range of 10 to 15 percent.

The SELECT Trial: The Game Changer

Every trial up to this point had been in patients with type 2 diabetes. The question was: does the heart protection depend on blood sugar improvement, or is something else going on? The SELECT trial answered that question definitively. It enrolled over 17,600 patients with obesity and established cardiovascular disease, but crucially, none of them had diabetes. Semaglutide at the 2.4 milligram dose (the same dose used in Wegovy) reduced the composite of cardiovascular death, heart attack, and stroke by 20 percent (hazard ratio 0.80). The hazard ratio for death from any cause was 0.81, representing a 19 percent reduction. A follow-up analysis showed that the cardiovascular benefit was consistent regardless of baseline HbA1c and regardless of whether HbA1c changed during the trial. That means the heart protection is not just a side effect of better blood sugar. Something deeper is happening. SELECT was the trial that led to the FDA approving Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease and obesity or overweight, regardless of diabetes status.

The SOUL Trial: Oral Semaglutide

The most recent major trial is SOUL, which tested oral semaglutide, a daily pill rather than an injection, in over 9,600 patients with type 2 diabetes and established cardiovascular or kidney disease. Over a mean follow-up of nearly four years, oral semaglutide reduced major adverse cardiovascular events by 14 percent (hazard ratio 0.86). The benefit was driven primarily by a 26 percent reduction in nonfatal heart attacks (hazard ratio 0.74). A secondary analysis showed that oral semaglutide produced early and sustained improvements in multiple cardiovascular risk factors, including HbA1c, bodyweight, systolic blood pressure, high-sensitivity C-reactive protein, and triglycerides. SOUL confirmed that the cardiovascular protection of GLP-1 medications extends to the oral formulation. The cardiovascular benefit was also consistent regardless of whether patients were taking an SGLT2 inhibitor, suggesting the two drug classes provide additive protection.

The Meta-Analysis: 71,000 Patients, One Consistent Answer

When all the major trials are pooled together, the numbers are remarkably consistent. A 2025 systematic review and meta-analysis of 10 trials enrolling over 71,000 patients found that long-acting GLP-1 receptor agonists reduce:

• Major adverse cardiovascular events (MACE) by 14 percent (hazard ratio 0.86)
• Heart failure hospitalizations by 14 percent (hazard ratio 0.86)
• Composite kidney outcome by 17 percent (hazard ratio 0.83)
• All-cause mortality by 12 percent (hazard ratio 0.88)

A consistent 14 percent reduction was seen for all individual MACE components: cardiovascular death, nonfatal heart attack, and nonfatal stroke. There was no significant heterogeneity by GLP-1 medication administration route, meaning both injectable and oral formulations provide cardiovascular protection. There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. These are not marginal effects. These are clinically meaningful reductions in the events that kill people.

Mechanism 1: Blood Pressure Reduction

GLP-1 medications lower systolic blood pressure by about 2 to 5 millimeters of mercury. That may sound modest, but at a population level, even small blood pressure reductions translate into meaningful reductions in heart attacks and strokes. The blood pressure effect comes partly from weight loss, but also from direct mechanisms, including improved sodium handling by the kidneys and better blood vessel function. The SOUL trial showed a sustained systolic blood pressure reduction of 1.83 mmHg and a pulse pressure reduction of 2.17 mmHg at three years compared to placebo.

Mechanism 2: Endothelial Function and Nitric Oxide

GLP-1 receptors are present on the cells lining blood vessels, the endothelium. When activated, they increase nitric oxide production, which causes blood vessels to relax and dilate. Research in animal models has shown that this endothelial GLP-1 receptor is actually required for the cardiovascular protection. When the endothelial GLP-1 receptor was knocked out in mice, the cardiovascular benefits of liraglutide disappeared entirely. When only the immune cell GLP-1 receptor was knocked out, the benefits persisted. This means the blood vessel lining, not the immune system, is the critical site of action for cardiovascular protection. This is a remarkable finding. It tells us that GLP-1 medications are not just reducing risk factors. They are directly protecting the blood vessels themselves.

Mechanism 3: Anti-Inflammatory Effects

This may be the most important mechanism of all. GLP-1 medications significantly reduce C-reactive protein (CRP), a key marker of systemic inflammation, by roughly 20 to 40 percent. They also reduce TNF-alpha and interleukin-6, two inflammatory cytokines that drive atherosclerosis. The SOUL trial showed that oral semaglutide reduced high-sensitivity CRP by 23 percent compared to placebo at three years. The SELECT trial showed that patients with higher baseline inflammatory burden (CRP of 2.0 mg/L or above) had particularly strong cardiovascular benefit. Inflammation is now recognized as a central driver of atherosclerosis. The landmark CANTOS trial proved that reducing inflammation alone, without changing cholesterol, reduces heart attacks. GLP-1 medications appear to provide a similar anti-inflammatory benefit alongside their other effects. Exploratory mediation analyses from the LEADER and REWIND trials suggested that reductions in HbA1c and albuminuria partially mediate the cardiovascular benefits, but the anti-inflammatory effect appears to be an independent contributor.

Mechanism 4: Cholesterol and Triglyceride Improvement

GLP-1 medications modestly lower LDL cholesterol and triglycerides. They also reduce the production of chylomicrons, the fat particles the body makes after eating, and VLDL particles from the liver. Cleaner blood lipids mean less raw material for plaque buildup. The SOUL trial showed sustained reductions in triglycerides and improvements in the overall lipid profile at three years. While the lipid effects are modest compared to statins, they contribute to the overall cardiovascular protection as part of the multi-mechanism approach.

Mechanism 5: Plaque Stabilization

Inside arteries, GLP-1 medications reduce the activity of matrix metalloproteinases, enzymes that can digest the fibrous cap holding a plaque together. A ruptured plaque is what causes most heart attacks. By stabilizing plaques, GLP-1 medications may prevent the acute events that are most dangerous. This mechanism is particularly important because it addresses the most lethal aspect of atherosclerosis: not the gradual narrowing of arteries, but the sudden rupture of an unstable plaque that triggers a blood clot and blocks blood flow entirely.

Mechanism 6: Direct Effects on Immune Cells

GLP-1 medications reduce the infiltration of inflammatory immune cells into artery walls, decrease macrophage content within plaques, and suppress the secretion of inflammatory cytokines from foam cells. This calms the inflammatory fire inside the vessel wall that drives atherosclerosis forward. Research has shown that GLP-1 medications reduce atherosclerosis progression and inflammatory biomarkers even in subjects without diabetes or obesity, and that the reduction in inflammatory markers partly mediates the reduction in cardiovascular events. Together, these six mechanisms explain why GLP-1 medications protect the heart through pathways that go far beyond weight loss or blood sugar control. They are working on the blood vessels, the immune system, the inflammatory cascade, the lipid profile, and the structural integrity of arterial plaques simultaneously.

Heart Failure: STEP-HFpEF and SUMMIT

Beyond atherosclerotic disease, GLP-1 medications are showing remarkable benefits in heart failure, specifically heart failure with preserved ejection fraction, or HFpEF. This is the type of heart failure most closely linked to obesity, and it has historically been very difficult to treat. In the STEP-HFpEF trials, semaglutide dramatically improved symptoms, quality of life, and exercise capacity in patients with HFpEF and obesity. Patients reported feeling significantly better and were able to do more physically. In the SUMMIT trial, tirzepatide (the dual GIP/GLP-1 agonist used in Mounjaro and Zepbound) reduced the composite of cardiovascular death or worsening heart failure by 38 percent in patients with HFpEF and obesity. This is a large effect size for a heart failure trial. A pooled analysis of these trials confirmed that GLP-1 and related medications represent a genuinely new treatment option for this challenging condition. For patients with obesity-related heart failure, these medications address the root cause, excess adiposity and its metabolic consequences, rather than just managing symptoms.

What This Means for You

GLP-1 medications are not heart drugs by accident. They are protecting the cardiovascular system through multiple simultaneous mechanisms: lowering blood pressure, improving blood vessel function, reducing inflammation, improving lipids, stabilizing plaques, and calming immune activity inside artery walls. The clinical trial evidence, from LEADER to SUSTAIN 6 to SELECT to SOUL, is deep, consistent, and growing. Over 71,000 patients across 10 randomized trials. A 14 percent reduction in heart attacks, strokes, and cardiovascular death. A 12 percent reduction in all-cause mortality. And a 20 percent reduction in cardiovascular events even in patients without diabetes. If you are on a GLP-1 medication, your heart is getting protection that goes far beyond weight loss. And if you have established cardiovascular disease and obesity, the SELECT trial data suggest that these medications should be part of the conversation with your doctor, regardless of whether you have diabetes. That is something worth knowing.